

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Prevention of liver fibrosis and steatosis progression among heavy drinkers with and without
HIV after 30-day drinking-reduction program

Seungjun Ahn^{1,3*}, Veronica Richards^{2,3,7}, Emmanuel Thomas⁴, Dushyantha Jayaweera⁴, Varan
Govind⁶, Zhigang Li^{1,3}, Ronald A. Cohen^{3,5}, Robert L. Cook^{2,3}.

¹Department of Biostatistics, University of Florida, Gainesville, FL 32611, U.S.A.

²Department of Epidemiology, University of Florida, Gainesville, FL 32611, U.S.A.

³Southern HIV and Alcohol Research Consortium, Emerging Pathogens Institute, Gainesville,
FL 32610, U.S.A.

⁴Schiff Center for Liver Disease, University of Miami Miller School of Medicine, Miami, FL
33136, U.S.A.

⁵Department of Clinical and Health Psychology, University of Florida, Gainesville, FL 32610,
U.S.A.

⁶Department of Radiology, University of Miami Miller School of Medicine, Miami, FL 33136,
U.S.A.

⁷Edna Bennett Pierce Prevention Research Center, Pennsylvania State University, University
Park, PA 16802, U.S.A.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

*Corresponding Author:

E-mail: sahn1@ufl.edu (S.A.)

32 **Abstract**

33 **Background:** This is the first attempt to assess changes in liver abnormalities before and after
34 contingency management (CM) to reduce heavy drinking beyond 30-days of follow-up.

35 **Objective:** The main objective was to determine whether liver fibrosis and steatosis, measured
36 using FibroScan, change significantly between baseline, 30-days, and 90-days among older
37 adults who drink heavily at baseline, enrolled in the CM intervention for alcohol reduction. The
38 secondary aim of the study was to assess whether the changes in liver outcome measures differ
39 across alcohol consumption categories.

40 **Methods:** A prospective study (ClinicalTrials.gov registry: NCT03353701) of 46 older adults
41 (63% male, 76.1% Black, mean age = 56.4) with heavy drinking at the baseline, living with or
42 without HIV infection was evaluated. A linear mixed-effects model was used to analyze the
43 FibroScan Transient Elastography (TE for fibrosis) and Controlled Attenuation Parameter (CAP
44 for steatosis).

45 **Results:** There were no significant changes in liver fibrosis and steatosis measures after 90-days
46 of drinking abstinence among heavy drinkers with or without stratified TE or CAP values at
47 baseline.

48 **Conclusions:** CM for drinking reduction may not be effective at least short-term prospective in
49 preventing liver fibrosis and steatosis progression for subjects without severe liver disease at
50 baseline.

51

52

53

54

55

56

57

58 **Abbreviations:** CM, contingency management; TE, Transient elastography; CAP, Controlled
59 attenuation parameter; HIV, Human immunodeficiency virus; PLWH, Persons living with HIV;
60 NAFLD, Non-alcoholic fatty liver disease; ALT, aminotransferase; GGT, gamma-glutamyl
61 transferase; ALD, Alcoholic-related liver disease; FIB-4, Fibrosis-4; AST, Aspartate
62 aminotransferase; TLFB, Alcohol timeline followback; HCV, Hepatitis C

63 **Introduction**

64 Alcohol use is the third leading preventable cause of death in the United States [1, 2]. Heavier
65 alcohol use has consistently been reported to be associated with increased risk for numerous
66 chronic diseases and conditions, such as liver diseases [3, 4, 5, 6]. With respect to liver diseases,
67 alcohol-attributable mortality from liver cirrhosis, an advanced stage of liver fibrosis, accounted
68 for 47.9 percent of all liver cirrhosis deaths worldwide (493,300 deaths) [3]. Liver steatosis (fatty
69 liver) is detected in 90% of people with heavy alcohol consumption [5, 7]. Although liver
70 steatosis is usually asymptomatic [5], it can progress to liver inflammation and liver cirrhosis [8].
71 Though the relationship between heavy alcohol consumption and liver diseases are an
72 established public health concern, it is unclear how reducing or ceasing from alcohol
73 consumption is associated with prevention of liver outcomes progression, warranting further
74 investigation.

75
76 Alcohol use is prevalent among persons living with HIV (PLWH) [9, 10], which is also
77 associated with incidence of liver disease [9]. Liver disease is one of the leading causes of death
78 among PLWH [10]. A recent cohort study [11] noted that the prevalence of liver diseases among
79 PLWH were 10 times higher compared with HIV-negative counterparts. A systematic review
80 [12] reported that the prevalence of non-alcoholic fatty liver disease (NAFLD) and fibrosis were
81 35% and 22% in PLWH, respectively. Moreover, HIV is associated with steatosis [13] and
82 chronic systemic inflammation, which may place PLWH at higher risk for developing liver
83 disease [14].

84
85 A review article [15] highlighted the need of intervention for drinking reduction and for better
86 understanding of HIV-related health outcomes at individual and policy levels. Contingency
87 management (CM) is one drinking intervention that has been effective for alcohol reduction [16,
88 17]. CM involves providing financial or other incentives for meeting a treatment goal or, a
89 negative consequence if the individual is unable to meet this goal. However, there is limited
90 published information about how short-term alcohol interventions, such as CM, may impact liver
91 disease, especially in PLWH and in the persons without severe liver disease at baseline. Among
92 two populations of “healthy” individuals who drank moderately-to-heavily, short-term
93 abstinence (one month) from alcohol resulted in significantly reduced serum alanine

94 aminotransferase (ALT) and gamma-glutamyl transferase (GGT), both indicating improvement
95 in liver function [18, 19]. The study outcomes for these two studies were assessed only at 30-
96 days, so it is unclear if these benefits persisted after 30-days. Further, it is unclear whether any
97 benefits of alcohol reduction extended to prevent liver fibrosis and steatosis progression, key
98 manifestations of both alcoholic-related liver disease (ALD) and NAFLD.

99
100 The primary objective of this study was to determine whether liver fibrosis and steatosis,
101 measured using FibroScan, change significantly with alcohol reduction from a CM intervention,
102 over three time periods (baseline, 30-days, and 90-days) among older adults who drink heavily
103 with or without stratified liver fibrosis and steatosis values at baseline. In the current study, the
104 fibrosis-4 (FIB-4) index [20] was analyzed as an additional liver outcome measure. We
105 hypothesized that the patterns of change in liver outcome measures would differ in alcohol
106 consumption categories (*i.e. quit/reduced drinking vs. continued heavy drinking*) during the
107 course of study, observed by an interaction effect between alcohol intake and time from an
108 analysis. This study would increase knowledge and empirical evidence on the prevention of
109 progression in liver abnormalities, fibrosis and steatosis before and after the initiation of a
110 drinking abstinence program.

111

112 **Materials and Methods**

113 **Study Participants**

114 This prospective study included older adults (aged 50 to 75 years) with heavy drinking (≥ 14
115 drinks/week for women, ≥ 21 drinks/week for men) at the baseline, living with or without HIV
116 infection, and were enrolled in a clinical trial of drinking-reduction from 12/11/2017 to
117 11/16/2021. A description of the methods of drinking-reduction program, “30-Day Challenge
118 Study,” is available in ClinicalTrials.gov registry and is shown in Fig 1. The trial was registered
119 under ClinicalTrials.gov with registry date and number (11/27/2017) (NCT03353701)
120 respectively. In brief, the “30-Day Challenge Study” used CM with financial incentives to
121 measure the impact of changes in alcohol consumption on changes in neurocognitive disorders,
122 liver fibrosis, and other HIV-related comorbidities. All procedures in the “30-Day Challenge
123 Study” were approved by the central Institutional Review Board at University of Miami (Study

124 Number: 20170396). All study participants provided informed consent prior to participation. All
125 methods were carried out in accordance with relevant guidelines and regulations.

126

127 **Fig 1. Timeline of the 30-Day Challenge Study.** The data used in this analysis come from the
128 baseline, 30-day, and 90-day follow-up visits, with measures included listed below each
129 timepoint. The contingency management (CM) period began at Baseline and ended at the 30-day
130 follow-up.

131

132 This study analyzed data from the baseline, 30-day follow-up (post CM), and 90-day follow-up
133 visits. At the time of data retrieval (12/07/2021), the dataset included 56 participants, but 10 were
134 excluded from the analysis due to missing baseline ($n = 1$), or missing both 30-days and 90-days
135 follow-up data on alcohol consumption ($n = 8$), or AST level ($n = 1$). In summary, data were
136 included from 46 participants with complete information on alcohol intake and liver outcome
137 measures at baseline and at least one follow-up visit.

138

139 **Outcome Measures**

140 The outcome variables included the changes from baseline values on liver fibrosis measured by
141 transient elastography (TE), and steatosis measured by controlled attenuation parameter (CAP),
142 respectively. These quantitative measures were obtained using a FibroScan (Echosens, Paris,
143 France) from baseline, 30-days, and 90-days. Additionally, the fibrosis-4 (FIB-4) index [20], a
144 validated noninvasive test alternative to liver biopsy, was considered to further investigate the
145 trend in liver fibrosis, calculated as,

$$146 \quad FIB-4 = \frac{Age \times AST}{Platelet\ Count \times \sqrt{ALT}}$$

147 where AST = aspartate aminotransferase and ALT = alanine aminotransferase. Hence, the
148 changes from baseline value on FIB-4 was also considered as an outcome variable.

149

150 **Main Predictor**

151 Although abstinence is often regarded as the primary endpoint in alcohol use disorder treatment,
152 the prior studies [21, 22] have shown that reduced alcohol consumption at any level has also
153 been linked to improved health outcomes. Thus, we decided to examine alcohol consumption as

154 a dichotomous variable rather than a 3-level categorical variable. Alcohol intake categories were
155 derived from the Alcohol Timeline Followback (TLFB) [23] data in the previous 30-days. *Heavy*
156 *drinking* was defined as consuming more than 7 drinks per week for females and more than 14
157 drinks per week for males, based on the National Institute on Alcohol Abuse and Alcoholism
158 (NIAAA) guideline [24]; *reduced drinking* was defined as drinking level that did not qualify
159 as heavy drinking; 3) *quit drinking* if a participant did not drink during 30 days. In this study,
160 reduced and quit drinking categories are combined for the analysis.

161

162 **Covariates**

163 HIV diagnosis (negative or positive), body mass index (BMI), sex at birth (female or male), age
164 in continuous scale, and hepatitis C (HCV) were included as covariates in later multivariable
165 analysis. HCV antibody test was conducted at baseline and classified as positive or negative.
166 HCV was included as a covariate, as earlier research showed that the alcohol consumption is
167 related to the transmission of both HIV and HCV [25]. BMI was broken down into three
168 categories: underweight or normal ($BMI < 25.0$), overweight ($25.0 \leq BMI < 30.0$), and obese
169 ($BMI \geq 30$) based on the Centers for Disease Control and Prevention classification of
170 overweight and obesity guideline [26]. Previous studies have shown that obesity is the important
171 risk factor for NAFLD [8, 27].

172

173 **Statistical Methods**

174 A linear mixed-effects model with random intercept was used to determine the changes in
175 FibroScan (TE and CAP), and FIB-4 score while accounting for within-subject correlations. An
176 unstructured covariance matrix was used. The change in log-transformed values of TE and FIB-4
177 were used as outcomes after examining residual diagnostics and standard model assumptions
178 (normality). However, the results were back-transformed and presented in their original scales
179 for the purpose of simplicity. As a subgroup analysis, we performed similar analyses among
180 participants with abnormal baseline values of TE (≥ 7 kPa) and CAP (≥ 238 dB/m) [28, 29].

181

182 We firstly fitted the marginal models (unadjusted models) for each predictor variable to identify
183 covariates that are marginally associated with each liver outcome variable at $p < 0.10$ (forward
184 selection). Subsequently, multivariable models (adjusted models) included time, categorical

185 alcohol intake, interaction term with alcohol intake and time, and the covariates that were
186 significantly associated with each liver outcome variables from unadjusted models. Lastly,
187 backward elimination was applied to identify covariates that are associated with liver outcome
188 variables in adjusted models, including only covariates with $p < 0.05$. Time was treated as a
189 continuous variable.

190

191 Demographic characteristics were presented as mean and standard deviation (SD) for continuous
192 variables and frequencies with percentages for categorical variables. Results were considered
193 statistically significant when $p < 0.05$. All analyses were conducted using SAS version 9.4 (SAS
194 Institute, Inc., Cary, NC).

195

196 **Sample Size Considerations**

197 The sample size ($n = 46$) was based on availability of data during the time span of the database
198 retrieval. A sample size of 46 yielded 85.7% statistical power to detect a large effect size
199 (Cohen's $f = 0.5$), determined by repeated measures ANOVA with a significance level of 0.05. A
200 statistical power calculation was performed in R version 4.0.2 (R Foundation for Statistical
201 Computing, Vienna, Austria).

202

203 **Results**

204 **Demographic and Clinical Characteristics**

205 The baseline characteristics are summarized in Table 1. The final data included 46 participants.
206 Overall, the mean age of study participants was 56.4 years (SD = 4.7 years). A majority of
207 participants were diagnosed with HIV ($n = 28$; 60.9%) and were either overweight ($n = 15$;
208 32.6%) or obese ($n = 13$; 28.3%). Most participants were Black ($n = 35$; 76.1%) and male sex (n
209 = 29; 63.0%). With 9 and 3 missing values, a majority of participants smoked cigarettes ($n = 30$;
210 81.1%) and were HCV negative ($n = 38$; 88.4%) at the time of enrollment in the 30-Day
211 Challenge Study.
212 Approximately 20% of participants had mild ($n = 4$) or severe ($n = 5$) fibrosis and almost half (n
213 = 21; 45.6%) had steatosis. The majority of participants did not have fibrosis ($n = 27$; 58.7%)
214 based on FIB-4 index.

215

216 **Table 1. Baseline characteristics of study participants in the study.**

Characteristics	Total (n = 46)
Mean Age (SD) in years	56.4 (4.7)
Mean alcohol start age (SD) in years	18.9 (5.7)
Sex at birth n (%)	
Female	17 (37.0)
Male	29 (63.0)
Race n (%)	
Black/African-American	35 (76.1)
White	9 (19.6)
Multiracial	2 (4.4)
Drinking behavior n (%)	
> 14 drinks/week	46 (100.0)
> 28 drinks/week	38 (82.6)
Steatosis grade ^a n (%)	
No steatosis (S0)	25 (54.4)
Mild steatosis (S1)	3 (6.5)
Moderate steatosis (S2)	7 (15.2)
Severe steatosis (S3)	11 (23.9)
Fibrosis stage ^b n (%)	
No or mild scarring	37 (80.4)
Mild fibrosis	4 (8.7)
Severe fibrosis	5 (10.9)
FIB-4 categories ^c n (%)	
Absence of fibrosis	27 (58.7)
Inconclusive	16 (34.8)
Severe fibrosis	3 (6.5)
HIV diagnosis n (%)	
Negative	18 (39.1)
Positive	28 (60.9)
BMI ^d n (%)	
Underweight/Normal	18 (39.1)
Overweight	15 (32.6)
Obese	13 (28.3)
Hepatitis C* n (%)	
Negative (< 0.8)	38 (88.4)
Positive (> 0.9)	5 (11.6)

Current smoking status** <i>n</i> (%)	
No	7 (18.9)
Yes	30 (81.1)

217 Data reported as mean (SD) for continuous variables and frequencies with percentages for
218 categorical variables; SD = standard deviation.

219 Percentages may not add up to 100% due to rounding.

220 FIB-4 = Fibrosis-4 index; SD = standard deviation.

221 ^a S0: CAP < 238 dB/M; S1: 238 ≤ CAP < 260 dB/M; S2: 260 ≤ CAP < 293 dB/M; S3: CAP ≥
222 293 dB/M [30]

223 ^b No or mild scarring: 2 ≤ TE < 7.1 kPa; mild fibrosis: 7.1 ≤ TE < 9.5 kPa; severe fibrosis: TE ≥
224 9.5 kPa [30].

225 ^c Absence of fibrosis: FIB-4 < 1.45; inconclusive: 1.45 ≤ FIB-4 ≤ 3.25; severe fibrosis: FIB-4 >
226 3.25 [20].

227 ^d Underweight/normal: BMI < 25.0; overweight: 25.0 ≤ BMI < 30.0; obese: BMI ≥ 30.

228 * 3 missing values; ** 9 missing values.

229

230 **Unadjusted Models for Screening Covariates (Forward Selection of** 231 **Model Covariates)**

232 In the unadjusted model using the entire sample, age (type III $p = 0.047$) and sex (type III $p =$
233 0.019) were marginally associated with the the change in CAP. None of the covariates were
234 significantly associated with changes in TE or FIB-4.

235

236 In the marginal analysis using subsamples with abnormal baseline TE, HCV (type III $p = 0.010$)
237 and sex (type III $p = 0.015$) were significantly associated with change in TE. There were
238 marginal associations between FIB-4 and HCV (type III $p = 0.080$). None of covariates were
239 significantly associated with change in CAP in this subsample.

240 With subsamples of abnormal baseline CAP, age (type III $p = 0.009$), HIV (type III $p = 0.052$),
241 and BMI (type III $p = 0.012$) were significantly associated with change in CAP. There was
242 significant marginal association between FIB-4 and BMI (type III $p = 0.009$). Lastly, TE did not
243 have marginal association with any covariates.

244

245 Subsequently, marginally significant covariates were included in the initial multivariable model
246 for the backward elimination.

247

248 **Adjusted Models for Liver Outcomes Using Entire Samples ($n = 46$)**

249 The results presented in Table 2 indicate that there was no significant change in any of liver
 250 outcomes for every one-day increase in time regardless of the level of alcohol intake (interaction
 251 terms). Males had significantly smaller changes in levels of CAP ($\hat{\beta} = -22.90$; 95% CI of $\hat{\beta}$: -
 252 41.49, -4.301; $p = 0.017$), when compared to females. Older age was associated with greater
 253 changes in levels of CAP ($\hat{\beta} = 2.489$; 95% CI of $\hat{\beta}$: 0.538, 4.441; $p = 0.014$).

254

255 **Table 2. Changes in liver outcomes associated with changes in alcohol consumption at 30**
 256 **and 90 days among 46 adults participating in a contingency management study.**

Variables	Outcomes								
	Change in TE			Change in CAP			Change in FIB-4		
	exp ($\hat{\beta}$)	95% CI of exp ($\hat{\beta}$)	p-value	$\hat{\beta}$	95% CI of $\hat{\beta}$	p-value	exp ($\hat{\beta}$)	95% CI of exp ($\hat{\beta}$)	p-value
Main Predictors									
Time	1.000	0.997, 1.002	0.930	0.022	-0.321, 0.366	0.895	1.000	0.997, 1.003	0.913
Alcohol intake									
Continued heavy drinking	‡	‡	‡	‡	‡	‡	‡	‡	‡
Quit/Reduced drinking	1.080	0.849, 1.372	0.521	-22.96	-63.31, 17.40	0.255	1.053	0.795, 1.393	0.712
Time × I(Alcohol intake = Quit/Reduced drinking)	0.999	0.995, 1.002	0.485	0.343	-0.244, 0.931	0.243	0.999	0.995, 1.004	0.810
Baseline liver measure ^a	0.786	0.633, 0.977	0.031*	-0.246	-0.420, -0.072	0.007*	0.674	0.502, 0.905	0.010*
Covariates^b									
Age				2.489	0.538, 4.441	0.014*			
Sex at birth									
Female				‡	‡	‡			
Male				-22.90	-41.49, -4.301	0.017*			

257 All mixed-effects models included linear function of time, categorical alcohol intake, and an
 258 interaction term with categorical alcohol intake and time. An unstructured covariance structure
 259 was used.

260 The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the
 261 coefficient estimates.

262 ^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor
 263 for the fitted model for change in CAP as an outcome variable.

264 ^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex
 265 were firstly considered as potential confounders and to be selected from unadjusted models at the
 266 0.1 significance level. Selected covariates were then remained after backward elimination at the
 267 0.05 significance level.

268 TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 =
 269 Fibrosis-4 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval

270 * A p-value < 0.05 was considered statistically significant, unless otherwise noted.

271 ‡ Reference group for comparisons.

272

273

274

275 **Adjusted Models for Liver Outcomes with Abnormal Baseline TE**

276 **Samples ($n = 9$)**

277 The interaction terms of the mixed-effects model results using samples with abnormal baseline
 278 TE (Table 3) highlights that there were no significant changes in liver outcome measures with
 279 varying alcohol intake categories for every one-day increase in time. Of them, the greater change
 280 (increase) in FIB-4 from baseline for every one-day increase in time was observed for those who
 281 quit or reduced drinking ($\exp(\hat{\beta}) = 1.010$; 95% CI of $\exp(\hat{\beta})$: 0.999, 1.021; $p = 0.067$), when
 282 compared with continued heavy drinking, albeit not statistically significant. This implies that
 283 34.8% higher level of FIB-4 in quit or reduced drinking versus continued heavy drinking after 30
 284 days, calculated by $[\exp(30 * \hat{\beta})] * 100\%$.

285
 286 Sex ($p = 0.229$) and HCV ($p = 0.086$) were excluded from the final adjusted model after the
 287 backward elimination for TE. HCV was remained significant in the model for FIB-4 ($p = 0.006$)
 288 after the backward elimination.

289
 290 **Table 3. Changes in liver outcomes associated with changes in alcohol consumption at 30**
 291 **and 90 days among 9 adults with abnormal baseline TE ($TE \geq 7$) participating in a**
 292 **contingency management study.**

Variables	Outcomes								
	Change in TE			Change in CAP			Change in FIB-4		
	exp ($\hat{\beta}$)	95% CI of exp ($\hat{\beta}$)	p-value	$\hat{\beta}$	95% CI of $\hat{\beta}$	p-value	exp ($\hat{\beta}$)	95% CI of exp ($\hat{\beta}$)	p-value
Main Predictors									
Time	1.001	0.991, 1.012	0.741	-0.194	-1.396, 1.007	0.677	0.994	0.986, 1.001	0.072
Alcohol intake									
Continued heavy drinking	‡	‡	‡	‡	‡	‡	‡	‡	‡
Quit/Reduced drinking	1.747	0.630, 4.844	0.203	-29.60	-147.6, 88.37	0.524	0.400	0.179, 0.892	0.034*
Time \times I(Alcohol intake = Quit/Reduced drinking)	0.994	0.979, 1.010	0.383	1.055	-0.733, 2.843	0.177	1.010	0.999, 1.021	0.067
Baseline liver measure ^a	1.105	0.590, 2.072	0.681	-0.252	-0.925, 0.420	0.356	0.327	0.193, 0.553	0.004*
Covariates^b									
Hepatitis C									
Negative							‡	‡	‡
Positive							2.727	1.602, 4.641	0.006*

293 All mixed-effects models included linear function of time, categorical alcohol intake, and an
 294 interaction term with categorical alcohol intake and time. An unstructured covariance structure
 295 was used.

296 The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the
 297 coefficient estimates.

298 ^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor
 299 for the fitted model for change in CAP as an outcome variable.

300 ^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex
 301 were firstly considered as potential confounders and to be selected from unadjusted models at the

302 0.1 significance level. Selected covariate was then remained after backward elimination at the
 303 0.05 significance level.
 304 TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 =
 305 Fibrosis-4 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval.
 306 * A p-value < 0.05 was considered statistically significant, unless otherwise noted.
 307 ‡ Reference group for comparisons.
 308

309 **Adjusted Models for Liver Outcomes with Abnormal Baseline CAP**

310 **Samples ($n = 21$)**

311 In the mixed-effects model using samples with abnormal baseline CAP (Table 4), there was no
 312 statistically significant interaction effect of time and alcohol intake categories on changes in liver
 313 outcome measures. Although it was not statistically significant, it is noteworthy that the greater
 314 change (increase) in CAP from baseline for every one-day increase in time was observed for
 315 those who quit or reduced drinking ($\hat{\beta} = 0.315$; 95% CI of $\hat{\beta}$: -0.588, 1.218; $p = 0.465$), when
 316 compared with continued heavy drinking.

317
 318 BMI remained in the final adjusted model for CAP and FIB-4 after backward elimination. Obese
 319 ($\exp(\hat{\beta}) = 1.285$; 95% CI of $\exp(\hat{\beta})$: 1.079, 1.531; $p = 0.009$) participants had 28.5% significantly
 320 higher level of FIB-4 from baseline, comparing with those who were either underweight or
 321 normal. Lastly, HIV ($p = 0.174$) and age ($p = 0.066$) were excluded from the final adjusted
 322 models for CAP after the backward elimination.

323 **Table 4. Changes in liver outcomes associated with changes in alcohol consumption at 30**
 324 **and 90 days among 21 adults with abnormal baseline CAP (CAP \geq 238) participating in a**
 325 **contingency management study.**

Variables	Outcomes								
	Change in TE			Change in CAP			Change in FIB-4		
	exp ($\hat{\beta}$)	95% CI of exp ($\hat{\beta}$)	p-value	$\hat{\beta}$	95% CI of $\hat{\beta}$	p-value	exp ($\hat{\beta}$)	95% CI of exp ($\hat{\beta}$)	p-value
Main Predictors									
Time	0.998	0.992, 1.003	0.330	0.037	-0.365, 0.438	0.846	1.001	0.996, 1.007	0.549
Alcohol intake									
Continued heavy drinking	‡	‡	‡	‡	‡	‡	‡	‡	‡
Quit/Reduced drinking	0.855	0.546, 1.338	0.468	-16.28	-78.96, 46.41	0.584	1.047	0.754, 1.453	0.767
Time \times I(Alcohol intake = Quit/Reduced drinking)	1.001	0.994, 1.007	0.815	0.315	-0.588, 1.218	0.465	0.999	0.993, 1.005	0.699
Baseline liver measure ^a	0.830	0.653, 1.055	0.118	-0.473	-0.907, -0.038	0.035*	0.869	0.727, 1.040	0.115
Covariates^b									
BMI									

Underweight/Normal				‡	‡	‡	‡	‡	‡
Overweight				25.72	-0.735, 52.17	0.056	1.095	0.874, 1.371	0.399
Obese				51.15	17.13, 85.18	0.006 [†]	1.285	1.079, 1.531	0.009 [†]

326 All mixed-effects models included linear function of time, categorical alcohol intake, and an interaction
 327 term with categorical alcohol intake and time. An unstructured covariance structure was used.

328 The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the coefficient
 329 estimates.

330 ^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor for the
 331 fitted model for change in CAP as an outcome variable.

332 ^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex were firstly
 333 considered as potential confounders and to be selected from unadjusted models at the 0.1 significance
 334 level. Selected covariates were then remained after backward elimination at the 0.05 significance level.

335 TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 = Fibrosis-4
 336 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval.

337 * A p-value < 0.05 was considered statistically significant, unless otherwise noted.

338 † A Bonferroni-corrected p-value of 0.0167 was considered statistically significant results for BMI.

339 ‡ Reference group for comparison

340

341 Discussion

342 To our knowledge, this study is the first of its kind in the literature to evaluate liver abnormalities
 343 before and after CM to reduce heavy drinking beyond 30-days of follow-up. To date, no studies
 344 have examined whether reduction in drinking will have an effect in a population of persons
 345 without severe liver disease to start with, but who are at high risk for progression. In this study,
 346 the interaction term obtained in an analysis showed that there were no significant changes in
 347 liver abnormalities after 90-days of drinking abstinence or reduction among heavy drinkers with
 348 or without stratified TE and CAP values at baseline. This suggests that CM for drinking
 349 reduction may not be effective at least short-term prospective in improving liver fibrosis and
 350 steatosis for subjects with or without abnormal levels of TE or CAP. It is not surprising to see
 351 that the behavioral intervention has not always been successful in improving health outcomes. A
 352 recent study has shown that the dietary behavioral intervention to increase vegetable intake did
 353 not significantly reduce cancer progression in men with early-stage prostate cancer [31]. In
 354 addition, results of the meta-analysis suggested that a brief intervention on alcohol consumption
 355 did not substantially reduce cigarette smoking in terms of frequency of smoking and likelihood
 356 of smoking cessation [32]. Although we did not see an improvement in our study, it is
 357 noteworthy that there was no significant change in liver abnormalities over time. Therefore, the
 358 liver disease did not progress further stages. It remains a question whether our intervention is
 359 what prevented the disease progression.

360

361 Additional findings of this study have identified a number of covariates that are significantly
362 associated with liver outcome measures. Participants with HCV infection had substantially
363 higher levels of FIB-4 with stratified TE values at baseline, when compared with those without
364 HCV infection. It is important to note that none of the participants had advanced alcoholic liver
365 disease or acute alcoholic hepatitis at the time of study enrollment. Moreover, the majority of the
366 study participants were recruited from an HIV clinic, not a liver clinic. Thus, we may have less
367 opportunities to view improvement in liver outcomes.

368
369 This study has a number of limitations to be considered. First, the alcohol intake categories
370 variable was created based on the TLFB method to calculate average number of drinks per week.
371 A recall bias and social desirability bias in self-reported longitudinal number of drinks per day
372 may lead to an inaccurate estimation of parameter estimates of the model. This may be especially
373 true during the CM period, as contingencies were aligned with drinking abstinence. Second,
374 although our results will contribute future understanding on changes in liver outcome measures,
375 the fitted model was constructed using a dataset with a limited number of covariates and
376 relatively small sample size.

377
378 Future studies with a larger sample size and diverse cohort characteristics (*e.g.* adjusted
379 FibroScan scores by GGT and lifestyle variable such as health satisfaction or well-being) are
380 warranted to validate our findings.

381

382 **Acknowledgments**

383 We are grateful for the administrative support of Dr. Christine Frank and for the data
384 management support of Dr. Zhi Zhou and Mr. Alex Li at the Southern HIV and Alcohol
385 Research Consortium.

386

387 **References**

388 [1] O'Keefe JH, Bhatti SK, Bajwa A, DiNicolantonio JJ, Lavie CJ. Alcohol and cardiovascular
389 health: the dose makes the poison...or the remedy. *Mayo Clin Proc.* 2014;89(3):382-93. doi:
390 10.1016/j.mayocp.2013.11.005. PMID: 24582196.

- 391 [2] National Institute on Alcohol Abuse and Alcoholism (NIAAA). 2020. Alcohol and American
392 Society: A Complex Relationship. [accessed 2023 February 27].
393 [https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-impact-](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-impact-health)
394 [health](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-impact-health).
- 395 [3] Rehm J, Shield KD. Global alcohol-attributable deaths from cancer, liver cirrhosis, and injury
396 in 2010. *Alcohol Res.* 2013;35(2):174-83. PMID: 24881325.
- 397 [4] Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic Liver Disease: Pathogenesis and
398 Current Management. *Alcohol Res.* 2017;38(2):147-161. PMID: 28988570.
- 399 [5] Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical
400 perspective. *Liver Res.* 2018;2(4):161-172. doi: 10.1016/j.livres.2018.11.002. PMID: 31214376.
- 401 [6] Traversy G, Chaput JP. Alcohol Consumption and Obesity: An Update. *Curr Obes Rep.*
402 2015;4(1):122-30. doi: 10.1007/s13679-014-0129-4. PMID: 25741455.
- 403 [7] Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets.
404 *Gastroenterology.* 2011;141(5):1572-85. doi: 10.1053/j.gastro.2011.09.002. PMID: 21920463.
- 405 [8] Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for
406 advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. *World J Hepatol.*
407 2017;9(2):91-98. doi: 10.4254/wjh.v9.i2.91. PMID: 28144390.
- 408 [9] Barve S, Kapoor R, Moghe A, Ramirez JA, Eaton JW, Gobejishvili L, Joshi-Barve S,
409 McClain CJ. Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver
410 disease in HIV-infected patients. *Alcohol Res Health.* 2010;33(3):229-36. PMID: 23584064.
- 411 [10] Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease:
412 An update. *Hepatology.* 2015;62(6):1871-82. doi: 10.1002/hep.28150. PMID: 26340591.
- 413 [11] Nanditha NGA, Paiero A, Tafessu HM, St-Jean M, McLinden T, Justice AC, Kopec J,
414 Montaner JSG, Hogg RS, Lima VD. Excess burden of age-associated comorbidities among
415 people living with HIV in British Columbia, Canada: a population-based cohort study. *BMJ*
416 *Open.* 2021;11(1):e041734. doi: 10.1136/bmjopen-2020-041734. PMID: 33419911.
- 417 [12] Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors
418 of nonalcoholic fatty liver disease in HIV-monoinfection. *AIDS.* 2017;31(11):1621-1632. doi:
419 10.1097/QAD.0000000000001504. PMID: 28398960.
- 420 [13] Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. *AIDS Patient*
421 *Care STDS.* 2005;19(6):356-65. doi: 10.1089/apc.2005.19.356. PMID: 15989431.

- 422 [14] Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. *BMJ*
423 *Open Gastroenterol.* 2017;4(1):e000166. doi: 10.1136/bmjgast-2017-000166. PMID: 29119002.
- 424 [15] Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol Use and Human
425 Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future
426 Directions. *Alcohol Clin Exp Res.* 2016;40(10):2056-2072. doi: 10.1111/acer.13204. PMID:
427 27696523.
- 428 [16] Dougherty DM, Hill-Kapturczak N, Liang Y, Karns TE, Cates SE, Lake SL, Mullen J,
429 Roache JD. Use of continuous transdermal alcohol monitoring during a contingency
430 management procedure to reduce excessive alcohol use. *Drug Alcohol Depend.* 2014;142:301-
431 306. doi: 10.1016/j.drugalcdep.2014.06.039. PMID: 25064019.
- 432 [17] Barnett NP, Celio MA, Tidey JW, Murphy JG, Colby SM, Swift RM. A preliminary
433 randomized controlled trial of contingency management for alcohol use reduction using a
434 transdermal alcohol sensor. *Addiction.* 2017;112(6):1025-1035. doi: 10.1111/add.13767. PMID:
435 28107772.
- 436 [18] Mehta G, Macdonald S, Cronberg A, Rosselli M, Khera-Butler T, Sumpter C, Al-Khatib S,
437 Jain A, Maurice J, Charalambous C, Gander A, Ju C, Hakan T, Sherwood R, Nair D, Jalan R,
438 Moore KP. Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver
439 function tests and cancer-related growth factors: a prospective observational study. *BMJ Open.*
440 2018;8(5):e020673. doi: 10.1136/bmjopen-2017-020673. PMID: 29730627.
- 441 [19] Munsterman ID, Groefsema MM, Weijers G, Klein WM, Swinkels DW, Drenth JPH,
442 Schellekens AFA, Tjwa ETTL. Biochemical Effects on the Liver of 1 Month of Alcohol
443 Abstinence in Moderate Alcohol Consumers. *Alcohol Alcohol.* 2018;53(4):435-438. doi:
444 10.1093/alcalc/agy031. PMID: 29726886.
- 445 [20] Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M,
446 Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical
447 Investigators. Development of a simple noninvasive index to predict significant fibrosis in
448 patients with HIV/HCV coinfection. *Hepatology.* 2006;43(6):1317-25. doi: 10.1002/hep.21178.
449 PMID: 16729309.
- 450 [21] Witkiewitz K, Kranzler HR, Hallgren KA, O'Malley SS, Falk DE, Litten RZ, Hasin DS,
451 Mann KF, Anton RF. Drinking Risk Level Reductions Associated with Improvements in

- 452 Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. *Alcohol Clin*
453 *Exp Res.* 2018;42(12):2453-2465. doi: 10.1111/acer.13897. PMID: 30395350.
- 454 [22] Henssler J, Müller M, Carreira H, Bschor T, Heinz A, Baethge C. Controlled drinking-non-
455 abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-
456 analysis and meta-regression. *Addiction.* 2021;116(8):1973-1987. doi: 10.1111/add.15329.
457 PMID: 33188563.
- 458 [23] Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline
459 Followback when administered by telephone and by computer. *Drug Alcohol Depend.*
460 1996;42(1):49-54. doi: 10.1016/0376-8716(96)01263-x. PMID: 8889403.
- 461 [24] National Institute on Alcohol Abuse and Alcoholism (NIAAA). 2021. Rethinking drinking:
462 Alcohol and your health. [accessed 2023 February 10].
463 https://www.niaaa.nih.gov/sites/default/files/publications/NIAAA_RethinkingDrinking.pdf
- 464 [25] Silverstein PS, Kumar S, Kumar A. HIV-1, HCV and alcohol in the CNS: potential
465 interactions and effects on neuroinflammation. *Curr HIV Res.* 2014;12(4):282-92. doi:
466 10.2174/1570162x12666140721122956. PMID: 25053363.
- 467 [26] National Heart, Lung, and Blood Institute (NHLBI). 2013. Managing overweight and
468 obesity in Adults: systematic evidence review from the obesity expert panel. [accessed 2023
469 February 8]. [https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-](https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-review.pdf)
470 [review.pdf](https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-review.pdf).
- 471 [27] Loomis AK, Kabadi S, Preiss D, Hyde C, Bonato V, St Louis M, Desai J, Gill JM, Welsh P,
472 Waterworth D, Sattar N. Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two
473 Electronic Health Record Prospective Studies. *J Clin Endocrinol Metab.* 2016;101(3):945-52.
474 doi: 10.1210/jc.2015-3444. PMID: 26672639.
- 475 [28] Scheiner B, Steininger L, Semmler G, Unger LW, Schwabl P, Bucsics T, Paternostro R,
476 Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Controlled attenuation parameter does not
477 predict hepatic decompensation in patients with advanced chronic liver disease. *Liver Int.*
478 2019;39(1):127-135. doi: 10.1111/liv.13943. PMID: 30107095.
- 479 [29] Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in
480 Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology.* 2019;156(5):1264-1281.e4.
481 doi: 10.1053/j.gastro.2018.12.036. PMID: 30660725.

- 482 [30] Sansom SE, Martin J, Adeyemi O, Burke K, Winston C, Markham S, Go B, Huhn G.
483 Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation
484 Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency
485 Virus/HCV Coinfection in a Large US Hepatitis Clinic. *Open Forum Infect Dis*.
486 2019;6(4):ofz099. doi: 10.1093/ofid/ofz099. PMID: 30968054.
- 487 [31] Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK,
488 Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L,
489 Small EJ, Morris MJ, Pierce JP, Marshall J. Effect of a Behavioral Intervention to Increase
490 Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer:
491 The MEAL Randomized Clinical Trial. *JAMA*. 2020 Jan 14;323(2):140-148. doi:
492 10.1001/jama.2019.20207. PMID: 31935026; PMCID: PMC6990696.
- 493 [32] McCambridge J, Jenkins RJ. Do brief interventions which target alcohol consumption also
494 reduce cigarette smoking? Systematic review and meta-analysis. *Drug Alcohol Depend*. 2008
495 Aug 1;96(3):263-70. doi: 10.1016/j.drugalcdep.2008.03.011. Epub 2008 May 23. PMID:
496 18457926.

497

498 **Supporting Information**

499 **S1 Table. Crude descriptive statistics of liver outcome measures at baseline, 30-days, and**
500 **90-days.**

501

502 **S2 Table. Descriptive statistics of change in liver outcome measures at 30-days and 90-days**
503 **with quit/reduced and continued heavy drinking.**

504

505 **S3 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30**
506 **and 90 days among 46 adults participating in a contingency management study.**

507

508 **S4 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30**
509 **and 90 days among 9 adults with abnormal baseline TE ($TE \geq 7$) participating in a**
510 **contingency management study.**

511

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 19

512 **S5 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30**
513 **and 90 days among 21 adults with abnormal baseline CAP (CAP \geq 238) participating in a**
514 **contingency management study.**



- Questionnaire completed (demographics, smoking status)
- Height and weight collected
- 30-Day Timeline Followback
- Blood sample collected (liver enzymes)
- FibroScan conducted

- 30-Day Timeline Followback
- Blood sample collected (liver enzymes)
- FibroScan conducted

- 30-Day Timeline Followback
- Blood sample collected (liver enzymes)
- FibroScan conducted